CompletedPhase 2NCT04396496
Treatment of POEMS Syndrome With Daratumumab
Studying POEMS syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Arkansas
- Principal Investigator
- Frits van Rhee, MDUniversity of Arkansas
- Intervention
- Daratumumab Injection(drug)
- Enrollment
- 2 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2023
Study locations (1)
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Collaborators
Janssen Scientific Affairs, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04396496 on ClinicalTrials.govOther trials for POEMS syndrome
Additional recruiting or active studies for the same condition.